Raymond James Financial
DNA icon

Raymond James Financial’s Ginkgo Bioworks DNA Stock Holding History

Raymond James Financial’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,351
Closed -$165K – 5204
2025
Q3 		$165K Buy
11,351
+8,748
+336% +$105K ﹤0.01% 4666
2025
Q2 		$29.3K Buy
+2,603
New +$20.2K ﹤0.01% 5429

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's DNA Position: Q4 2025 in Review

Raymond James Financial sold out of Ginkgo Bioworks (DNA) in Q4 2025, closing a stake of 11,351 shares — an estimated $165K sold.

Raymond James Financial first reported a position in DNA in Q2 2025 and held it in 2 quarters. The position peaked at $165K in Q3 2025. 181 funds tracked by Wall St. Rank hold DNA as of Q4 2025.

  • Raymond James Financial reported no remaining Ginkgo Bioworks position as of Q4 2025 after selling out during the quarter.
  • Raymond James Financial sold 11,351 Ginkgo Bioworks shares in Q4 2025, an estimated $165K.
  • Raymond James Financial first reported a position in Ginkgo Bioworks in Q2 2025 and held it in 2 quarters.
  • Raymond James Financial's Ginkgo Bioworks position peaked at $165K in Q3 2025.
  • 181 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2025.

Based on Raymond James Financial's 13F filing for Q4 2025, filed 18 Feb 2026.